Clinical Validation of a Predictive Test for Postpartum Depression
Key facts
- Who runs it
- University of Virginia
- Where
- Charlottesville and Falls Church, United StatesSee the 2 sites
- Trial code
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- 20 Mar 2025
- Expected to end
- 31 Jul 2028
- Type of study
- Observational
- Treatments tested
- Enlighten
- Record updated
- 3 December 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- subject must be pregnant (singleton pregnancy)
- <30 weeks' gestation, age 18 or above
- able to provide written consent in English
Who cannot take part
- The study team and/or PI may exclude anyone deemed unsafe to participate in the protocol
This trial is currently available in United States.
- University of VirginiaCharlottesville, United StatesContact: Meeta Pangtey, MPHTaking people
- Inova Health SystemFalls Church, United StatesContact: Scott A Sullivan, MDTaking people
About the trial
What the trial wants to find out
The goal of this observational study is to develop a blood test that may be predictive of postpartum depression. This Blood test is investigational and not yet FDA approved. Participants will not receive the results of this blood test.
Read full original descriptionShow less
Up to 500 pregnant women will be recruited for the study from 2 sites. Participants must be age 18 or above with a singleton pregnancy and able to provide written consent in English.
The Objective of this Clinical Trial is to prospectively validate the Enlighten Device test by prospectively determining false/true positive and negative rates. Building off of this, an exploratory objective of this study is to examine clinical factors associated with false positive/negative rates.
This project will address the following Aim:
Aim 1: Prospective collection of true/false positive and negative PPD outcomes through 6 months postpartum.
Primary Hypothesis H1a: 80% or greater of pregnant women who develop PPD by 3 months after delivery will be determined to be Biomarker Positive by the Enlighten Device in T3.
Primary Hypothesis H1b: 10% or fewer of pregnant women who are determined to be Biomarker Negative by the Enlighten Device in T3 will develop PPD by 3 months after delivery.
Exploratory Aim 1: Investigation of clinical factors that may be associated with false positive and false negative rates, such as: medication use, stressful life events, and sociocultural context.
Participants will be screened during the second or third trimester and enrolled during the third trimester, before week 30 weeks of gestation. Participants may self- identify through study advertisements in participating clinics, social media outlets, and community outreach efforts. Enrolled participants will undergo blood collection during their 3rd trimester (~27-30 weeks, a standard pregnancy-related blood collection timepoint) for completion of the Enlighten Device test, the blood-based epigenetic biomarker test. Participants will then be interviewed at 2 weeks, 6 weeks, 3 months, and 6 months postpartum for the development of depression symptoms. They'll also complete a multitude of other outcome measures at each of these visits.
Treatments tested
- Enlighten
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 3 December 2025